Loading…
CG Oncology, Inc. is projected to rise to $113.98 by 2027, a +51% move from its current price of $75.24. CGON is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 14 | $73.35 | $75.29 | $77.28 | +0.07% |
| Jul 15 | $72.62 | $75.35 | $78.18 | +0.14% |
| Jul 16 | $72.07 | $75.40 | $78.88 | +0.21% |
| Jul 17 | $71.62 | $75.45 | $79.49 | +0.28% |
| Jul 18 | $71.23 | $75.50 | $80.04 | +0.35% |
| Jul 19 | $70.88 | $75.56 | $80.54 | +0.42% |
| Jul 20 | $70.57 | $75.61 | $81.01 | +0.49% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $70.57 | $75.61 | $81.01 | +0.49% |
| Week 2 | $68.92 | $75.98 | $83.77 | +0.99% |
| Week 3 | $67.75 | $76.36 | $86.05 | +1.48% |
| Week 4 | $66.84 | $76.73 | $88.09 | +1.98% |
| Week 5 | $66.08 | $77.11 | $89.98 | +2.49% |
| Week 6 | $65.44 | $77.49 | $91.77 | +2.99% |
| Week 7 | $64.87 | $77.87 | $93.47 | +3.50% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
CG Oncology, Inc. is a healthcare company described as a late-stage clinical biopharmaceutical company that develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The product candidate cretostimogene is an investigational oncolytic immunotherapy, in phase 2 clinical trials for high-risk NMIBC after BCG failure and in phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in high-risk NMIBC and BCG-unresponsive settings.
The company was formerly Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020.
CG Oncology was founded in 2010 and is headquartered in Dallas, Texas.
CG Oncology, Inc. (CGON) is listed with a current price of $72.84 and operates in the Healthcare sector. The stock carries a market capitalization of $6.42B and ranks 1192 in size.
The asset shows a long-term price outlook that begins near the current level and projects higher average prices over time. The forecasted path includes meaningful increases in average price from 2026 onward, with higher mid- and long-term targets.
A major floor 38.1% below — a decisive break under it would weaken the trend.
The nearest floor, 28.6% below — buyers have tended to step in here.
Price is pressing into resistance (0.0% away) — a breakout level to watch.
A major ceiling 19.1% above — clearing it would confirm fresh momentum.
Key CGON support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CGON market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $71.36 | Buy | $72.41 | Buy |
| MA 10 | $71.48 | Buy | $70.87 | Buy |
| MA 20 | $67.34 | Buy | $68.36 | Buy |
| MA 50 | $64.97 | Buy | $65.70 | Buy |
| MA 100 | $64.68 | Buy | $62.50 | Buy |
| MA 200 | $54.41 | Buy | $55.53 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 68.87 | Neutral |
| Stoch RSI (14) | 84.15 | Sell |
| CCI (20) | 109.12 | Buy |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.63 | Buy |
| ROC (12) | 14.47 | Buy |
| Bollinger %B (20,2) | 0.86 | Neutral |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | 0.51 | Buy |
| Awesome (5,34) | 7.65 | Buy |
| Ultimate (7,14,28) | 74.84 | Sell |
| Momentum (10) | 2.40 | Buy |
| Aroon Osc (25) | 92.00 | Buy |
| Hull MA (9) | 72.37 | Buy |
| ADX (14) | 23.96 | Buy |
| ATR (14) | 1.61 | Info |
The 30-day technical picture is described as BULLISH, with RSI14 at 70. The 50-day simple moving average is $64.49 and the 200-day simple moving average is $52.61, indicating longer-term momentum behind the move.
Support sits at $53.72 and resistance at $74.00, framing the near-term trading range. The 30-day range is $59.64 to $88.97, outlining the recent volatility band around the current price.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $40.04 | $75.24 | $111.64 | 0% | Neutral | |
| $91.11 | $113.98 | $150.60 | +51% | Bullish | |
| $102.47 | $131.62 | $180.21 | +75% | Bullish | |
| $114.01 | $149.70 | $210.75 | +99% | Bullish | |
| $130.34 | $174.49 | $251.48 | +132% | Bullish | |
| $142.18 | $193.72 | $284.97 | +157% | Bullish | |
| $172.34 | $238.71 | $357.66 | +217% | Bullish | |
| $210.72 | $296.38 | $451.52 | +294% | Bullish | |
| $235.03 | $335.43 | $518.92 | +346% | Bullish | |
| $263.59 | $381.48 | $598.61 | +407% | Bullish | |
| $417.07 | $642.94 | $1,071.04 | +755% | Bullish | |
| $738.17 | $1,267.82 | $2,304.59 | +15.9x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $40.04 | $75.24 | $90.90 | +0.00% |
| August 2026 | $67.38 | $79.43 | $96.07 | +5.56% |
| September 2026 | $67.59 | $80.21 | $98.06 | +0.99% |
| October 2026 | $67.80 | $80.92 | $99.82 | +0.88% |
| November 2026 | $70.99 | $85.15 | $105.83 | +5.23% |
| December 2026 | $74.04 | $89.21 | $111.64 | +4.77% |
Click any year to see its month-by-month CGON forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
CG Oncology, Inc.'s 2026 outlook centres on $75.24, within a $40.04 to $111.64 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, CGON could reach as high as $150.60, with a base case around $113.98 and support toward $91.11 — roughly +51% from $75.24. Buyers look set to stay in control over this stretch.
Expect CGON to range from $102.47 to $180.21 through 2028. The $131.62 average target implies a +75% move from current prices. That is up +15% on the projected 2027 average. Momentum favours further upside here.
The CGON price prediction for 2029 points to an average of $149.70 (low $114.01, high $210.75) — a potential gain of +99% on today's $75.24. Buyers look set to stay in control over this stretch.
In 2030, CGON is projected to trade between $130.34 and $251.48, averaging $174.49 — a potential gain of +132% from today's $75.24. That is up +17% on the projected 2029 average. Momentum favours further upside here.
CG Oncology, Inc.'s 2031 outlook centres on $193.72, within a $142.18 to $284.97 range. That is up +11% on the projected 2030 average. That marks a +157% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, CGON could reach as high as $357.66, with a base case around $238.71 and support toward $172.34 — roughly +217% from $75.24. Momentum favours further upside here.
Expect CGON to range from $210.72 to $451.52 through 2033. The $296.38 average target implies a +294% move from current prices. That is up +24% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The CGON price prediction for 2034 points to an average of $335.43 (low $235.03, high $518.92) — a potential gain of +346% on today's $75.24. Momentum favours further upside here.
In 2035, CGON is projected to trade between $263.59 and $598.61, averaging $381.48 — a potential gain of +407% from today's $75.24. That is up +14% on the projected 2034 average. Buyers look set to stay in control over this stretch.
CG Oncology, Inc.'s 2040 outlook centres on $642.94, within a $417.07 to $1,071.04 range. That is up +69% on the projected 2035 average. That marks a +755% change versus current levels. Momentum favours further upside here.
By 2050, CGON could reach as high as $2,304.59, with a base case around $1,267.82 and support toward $738.17 — roughly +15.9x from $75.24. Buyers look set to stay in control over this stretch.
Investing $1,000 in CGON today (≈ 13.290803 CGON) could be worth
$16,850.39
+$15,850.39 (+1585%) by 2050 · US Dollar
Based on the average projected CGON price of $1,267.82 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CGONwould be worth at today's price.
$1,000 invested in CGON on Jul 10, 2025 (≈ 36.886757 CGON) would be worth
$2,775.36
+$1,775.36 (+177.5%) today · 2.78× · US Dollar
Based on a CGON entry price of $27.11 vs. today's $75.24.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $70.36 | $1,069.36 | +6.9% |
| 1 month ago | $54.92 | $1,369.99 | +37.0% |
| 3 months ago | $67.7 | $1,111.37 | +11.1% |
| 6 months ago | $53.72 | $1,400.6 | +40.1% |
| 1 year ago | $27.11 | $2,775.36 | +177.5% |
| All time (2.5y) ago | $37.17 | $2,024.21 | +102.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CGON forecast.
Our base-case forecast reaches $150.00 around 2030.
Implied market cap at $150.00: $13.23B
The multi-year forecast shows a rising trajectory for CG Oncology, Inc. In 2026 the average price is projected at $72.84, with a 2027 average of $113.45 and a 2028 average of $135.02; by 2030 the average is $177.82 (ROI 144.1%).
By 2040 the forecast rises to an average of $716.92 (ROI 884.2%), and by 2050 the average is $1,383.75 (ROI 1,799.7%), with corresponding min/max values of $438.91/$1,254.04 for 2040 and $740.33/$2,664.65 for 2050. The sentiment remains BULLISH in 2040 and 2050, reflecting an expansive upside under the projected ranges, though these are estimates and not guarantees.
The forecast also shows notable year-by-year growth in the later years (for example 2027 min $89.25, max $153.21; 2029 min $111.37, max $217.31; 2032 min $172.47, max $384.57; 2035 min $265.75, max $657.86), underscoring a wide potential upside from the current level.
Tap a question to reveal the answer.
The 2030 average price is $177.82 with a min of $129.13, a max of $264.71, and an estimated ROI of 144.1%.
The forecast shows neutral sentiment for 2026 (average price $72.84) and bullish sentiment from 2027 onward, with 2027 average $113.45 and 2028 average $135.02, continuing higher through 2050.
Yes. The 2027 max is $153.21 and the 2027 average is $113.45, indicating a path that could exceed $150 within that year under the forecast.
Current price is $72.84 and market capitalization is $6.42B.
2040: average $716.92, min $438.91, max $1,254.04, ROI 884.2%, sentiment BULLISH. 2050: average $1,383.75, min $740.33, max $2,664.65, ROI 1,799.7%, sentiment BULLISH.
CG Oncology, Inc. Community Discussion
0Share your CG Oncology, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.